Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39930 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL515661 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL912891 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL23722964 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL561138 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL23515345 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL1578111 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL2723355 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL22777473 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL17932953 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | claimed |
| EP-2547355-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-01-11 | — | — | EP | claimed |
| EP-2470672-A1 | COMPOUND | The Queen's University of Belfast (GB) | 2012-07-04 | — | — | EP | claimed |
| US-20120156691-A1 | COMPOUND | QUEEN'S UNIVERSITY OF BELFAST | 2012-06-21 | — | — | US | claimed |
| WO-2011024006-A1 | COMPOUND | QUEEN'S UNIVERSITY OF BELFAST (GB) | 2011-03-03 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250243159-A9 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-07-31 | — | — | US | disclosed |
| EP-2470672-A1 | COMPOUND | The Queen's University of Belfast (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20120156691-A1 | COMPOUND | QUEEN'S UNIVERSITY OF BELFAST | 2012-06-21 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011024006-A1 | COMPOUND | QUEEN'S UNIVERSITY OF BELFAST (GB) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | LMNA 4762/4885BLM 3782/4885TSHR 1283/4885 |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | LMNA 1445/4885BLM 4480/4885TSHR 689/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | LMNA 4611/4885BLM 4444/4885TSHR 211/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | LMNA 2818/4885BLM 4487/4885TSHR 434/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | LMNA 2788/4885BLM 3228/4885TSHR 20/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | LMNA 4387/4885BLM 4137/4885TSHR 255/4885 |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | DNPEP, NPEPPS, PAM | LMNA 4762/4885BLM 3782/4885TSHR 1283/4885 |
| US-20250243159-A9 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MUC1, APOB, PLTP | LMNA 321/4885BLM 644/4885TSHR 1299/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | LMNA 4184/4885BLM 4297/4885TSHR 17/4885 |
| US-20120156691-A1 | COMPOUND | DNPEP, TMPRSS15, PEPD | LMNA 2269/4885BLM 3222/4885TSHR 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.